NCT05751629View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions

Ovarian Neoplasm

Interventions

DRUG

Dostarlimab

Dostarlimab was administered.

DRUG

Bevacizumab

Bevacizumab was administered.

DRUG

Niraparib

Niraparib was administered.

Trial Locations (10)

27710

GSK Investigational Site, Durham

35249

GSK Investigational Site, Birmingham

55905

GSK Investigational Site, Rochester

60637

GSK Investigational Site, Chicago

73104

GSK Investigational Site, Oklahoma City

90095

GSK Investigational Site, Los Angeles

93003

GSK Investigational Site, Ventura

94304

GSK Investigational Site, Palo Alto

02114

GSK Investigational Site, Boston

02215

GSK Investigational Site, Boston

All Listed Sponsors

lead

Tesaro, Inc.

INDUSTRY

NCT05751629 - Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter